Document text
Principal Investigator: MARK S SMELTZER
Organization: UNIV OF ARKANSAS FOR MED SCIS
Fiscal Year: 2024
Award: $228,000
Funding agency: National Institute of General Medical Sciences
PROJECT SUMMARY/ABSTRACT
A primary means of research support for investigators in the Center for Microbial Pathogenesis and Host
Inflammatory Responses (CMPHIR) in Phase III will be the NIGMS-funded Pilot Grant Program (PGP),
supplemented with institutional funds ($100,000 per year for each year) to support a Director's Innovation Fund.
The focus will be on identifying new investigators with research interests consistent with the scientific theme of
the CMPHIR. Support will be provided for projects that clearly fit within the scientific scope of the CMPHIR, with
a particular emphasis on investigators whose research is potentially synergistic with existing CMPHIR
investigators, thereby maximizing opportunities for the development of synergistic collaborations. We will also
continue the efforts we started in Phase II to support projects that address issues in infectious disease in the
most comprehensive fashion possible and one that can be integrated with the experimental foundation built in
Phases I and II. Included among specific areas of interest are projects investigating improved diagnostic
methods, the development of more effective antimicrobial drugs, the potential to repurpose approved drugs for
infectious disease applications, vaccine development, the development of biomaterials with anti-infective
properties, and understanding the impact of host comorbidities on the susceptibility to infection and the response
to therapeutic intervention. In addition, the PGP and Director's Innovation Fund will be used in support of highly
strategic external recruitment by other research units at UAMS recruiting new investigators with research
interests consistent with the scientific theme of the CMPHIR. This will allow the CMPHIR to continue to grow and
mature into a self-sustaining Center of Biomedical Research Excellence as we move forward into Phase III and
beyond.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Anti-Infective Agents><Anti-Infective Drugs><Anti-Infectives><Anti-infective Preparation><Antibiotic Resistance><Area><Arkansas><Bacteria><Bridging Award><COBRE><COVID-19 virus><COVID19 virus><Center of Biomedical Research Excellence><Centers of Research Excellence><Clinical><CoV-2><CoV2><Collaborations><Communicable Diseases><Development><Diagnostic Method><Diagnostic Procedure><Diagnostic Technique><Drugs><Elements><Ensure><Equation><Foundations><Funding><Generalized Growth><Goals><Grant><Growth><Health><Howard Temin Award><Human><Immune response><Immunological response><Immunology><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory Response><Institution><Investigators><Medical><Medication><Medicine><Microbiology><Mission><Modern Man><NIGMS><National Institute of General Medical Sciences><Parasites><Pathogenesis><Pharmaceutical Preparations><Phase><Play><Predisposition><Prevalence><Property><Publications><Research><Research Infrastructure><Research Personnel><Research Support><Researchers><Resistance to antibiotics><Resistant to antibiotics><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Scientific Publication><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Side><Susceptibility><Therapeutic><Therapeutic Intervention><Tissue Growth><Universities><Variant><Variation><Virus><Wuhan coronavirus><adverse consequence><adverse outcome><anti-microbial agent><anti-microbial drug><antibiotic drug resistance><antibiotic resistant><biomaterial development><co-morbid><co-morbidity><communicable disease control agent><comorbidity><coronavirus disease 2019 virus><coronavirus disease-19 virus><develop a vaccine><develop vaccines><development of a vaccine><developmental><drug/agent><hCoV19><host response><immune system response><immunoresponse><improved><innovate><innovation><innovative><interest><intervention therapy><microbe pathogen><microbial><microbial pathogen><nCoV2><novel><ontogeny><pathogen><pathogenic microbe><programs><prophylactic><recruit><recruitment science><resistance strain><resistant strain><response><success><vaccine development>